Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

Perrin, Richard J.; Fagan, Anne M.; Holtzman, David M.

doi:10.1038/nature08538

Cited by 703Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

Open access

Perrin, Richard J., Fagan, Anne M., Holtzman, David M.·2009·Nature

DOI 10.1038/nature08538PMC PMC2810658

Open this paper in CoChat — free account

Abstract

Alzheimer's disease affects millions of people around the world. Currently, there are no treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's disease is characterized by protein misfolding in the brain. This process and the associated brain damage begin years before the substantial neurodegeneration that accompanies dementia. Studies using new neuroimaging techniques and fluid biomarkers suggest that Alzheimer's disease pathology can be detected preclinically. These advances should allow the design of new clinical trials and early mechanism-based therapeutic intervention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature08538

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

AD pathology, such as cerebral Aβ accumulation, probably begins one to two decades before onset of clinical symptoms.
“Growing evidence suggests that AD pathology, such as cerebral Aβ accumulation, probably begins one to two decades before onset of clinical symptoms (Holtzman et al. 2011, Perrin et al. 2009).”
From miR‐186 is decreased in aged brain and suppresses <scp>BACE</scp>1 expression (2016) · cites this paper as Perrin et al. 2009

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882 · see citing works
The Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761 · see citing works
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · see citing works
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works
Searching for a baseline: Functional imaging and the resting human brain
Gusnard, D. A., & Raichle, M. E. (2001) · Nature Reviews Neuroscience · doi:10.1038/35094500 · Cited by 3,371 · see citing works
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859 · see citing works
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · see citing works
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · see citing works
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1× · see citing works
“The onset of very mild dementia is correlated best not with plaque or NFT burden but with significant synaptic and neuronal los”
Background
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656 · see citing works
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · see citing works
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported
Evans, D. A. (1989) · JAMA · doi:10.1001/jama.262.18.2551 · Cited by 1,627 · see citing works
Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542 · see citing works
Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease
Simard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265 · see citing works
Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265 · see citing works
Self-citation
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works
Self-citation
Prevalence of Alzheimer's Disease in a Community Population of Older Persons: Higher Than Previously Reported
Evans, D. A. (1989) · JAMA · doi:10.1001/jama.1989.03430180093036 · Cited by 1,226 · see citing works
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · see citing works
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · see citing works
Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987 · see citing works
Self-citation
Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · see citing works
Self-citation
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · see citing works
Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease
Abraham, C. R., Selkoe, D. J., & Potter, H. (1988) · Cell · doi:10.1016/0092-8674(88)90462-x · Cited by 893 · see citing works
Hippocampal and entorhinal atrophy in mild cognitive impairment
Devanand, D. P., Pradhaban, G., Liu, X., Khandji, A., Santi, S. D., Segal, S., Rusinek, H., Pelton, G. H., Honig, L. S., Mayeux, R. P., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000256697.20968.d7 · Cited by 752 · see citing works
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., Lavretsky, H., Burggren, A. C., Cole, G. M., Vinters, H. V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054625 · Cited by 731 · see citing works
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works
Clinical Dementia Rating (CDR)
Gauthier, S. G. (2001) · CRC Press eBooks · doi:10.3109/9780203213896-34 · Cited by 696 · see citing works
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · see citing works
Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works
Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- <scp>d</scp> -glucose/positron-emission tomography (FDG/PET)
de Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y., DeSanti, S., Rusinek, H., Tsui, W., Kandil, E., Scherer, A. J., Roche, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191044198 · Cited by 629 · see citing works
Mild cognitive impairment
Chételat, G., Desgranges, B., Sayette, V. D. L., Viader, F., Eustache, F., & Baron, J. (2003) · Neurology · doi:10.1212/01.wnl.0000055847.17752.e6 · Cited by 604 · see citing works
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.
Evans, D. A., Funkenstein, H. H., Albert, M., Scherr, P. A., Cook, N. R., Chown, M. J., Hebert, L. E., Hennekens, C. H., & Taylor, J. O. (1989) · PubMed · Cited by 599 · see citing works
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599 · see citing works
Self-citation
Clinico‐pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease
Crystal, H., Dickson, D., Fuld, P., Masur, D., Scott, R., Mehler, M., Masdeu, J., Kawas, C., Aronson, M., & Wolfson, L. (1988) · Neurology · doi:10.1212/wnl.38.11.1682 · Cited by 586 · see citing works
Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease
Morris, J. C., & Price, J. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:101 · Cited by 513 · see citing works
Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513 · see citing works
Proteome-based plasma biomarkers for Alzheimer's disease
Hye, A., Lynham, S., Thambisetty, M., Čaušević, M., Campbell, J., Byers, H. L., Hooper, C., Rijsdijk, F. V., Tabrizi, S. J., Banner, S. J., et al. (2006) · Brain · doi:10.1093/brain/awl279 · Cited by 463 · see citing works
Inflammatory markers and the risk of Alzheimer disease: The Framingham Study
Tan, Z. S., Beiser, A. S., Vasan, R. S., Roubenoff, R., Dinarello, C. A., Harris, T. B., Benjamin, E. J., Au, R., Kiel, D. P., Wolf, P. A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000263217.36439.da · Cited by 440 · see citing works
Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease
Graff‐Radford, N. R., Crook, J. E., Lucas, J. A., Boeve, B. F., Knopman, D. S., Ivnik, R. J., Smith, G. E., Younkin, L. H., Petersen, R. C., & Younkin, S. G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.354 · Cited by 440 · see citing works
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405 · see citing works
Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: Insights from functional MRI studies
Dickerson, B. C., & Sperling, R. A. (2007) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2007.11.030 · Cited by 375 · see citing works
Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327 · see citing works
Self-citation
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322 · see citing works
Self-citation
Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma
Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301 · see citing works
Amyloid-β Dynamics Correlate with Neurological Status in the Injured Human Brain
Brody, D. L., Magnoni, S., Schwetye, K. E., Spinner, M. L., Esparza, T. J., Stocchetti, N., Zipfel, G. J., & Holtzman, D. M. (2008) · Science · doi:10.1126/science.1161591 · Cited by 295 · see citing works
Self-citation
CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 274 · see citing works
The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT
Hirao, K., Ohnishi, T., Hirata, Y., Yamashita, F., Mori, T., Moriguchi, Y., Matsuda, H., Nemoto, K., Imabayashi, E., Yamada, M., et al. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.06.066 · Cited by 264 · see citing works
Biomarkers of Alzheimer's disease
Craig‐Schapiro, R., Fagan, A. M., & Holtzman, D. M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.003 · Cited by 217 · see citing works
Self-citation
Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease
Mehta, P., Pirttilä, T., Patrick, B., Barshatzky, M., & Mehta, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01754-2 · Cited by 203 · see citing works
Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients
Davidsson, P., Brinkmalm, A., Nilsson, C. L., Lindbjer, M., Paulson, L., Andreasen, N., Gren, M., & Blennow, K. (2002) · Neuroreport · doi:10.1097/00001756-200204160-00015 · Cited by 200 · see citing works
Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease
Finehout, E. J., Franck, Z., Choe, L. H., Relkin, N. R., & Lee, K. H. (2006) · Annals of Neurology · doi:10.1002/ana.21038 · Cited by 185 · see citing works
Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease
Zhang, J., Goodlett, D. R., Quinn, J. F., Peskind, E. R., Kaye, J. A., Zhou, Y. F., Pan, C., Yi, E. C., Eng, J. K., Wang, Q., et al. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7205 · Cited by 174 · see citing works
Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease
Fox, N. C., Warrington, E. K., & Rossor, M. N. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00496-1 · Cited by 162 · see citing works
Peripheral Inflammatory Cytokines as Biomarkers in Alzheimer’s Disease and Mild Cognitive Impairment
Guerreiro, R. J., Santana, I. J., Brás, J., Santiago, B., Paiva, A. A., & Oliveira, C. R. (2007) · Neurodegenerative Diseases · doi:10.1159/000107700 · Cited by 150 · see citing works
Development of a New Radioligand, N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for PET Imaging of Peripheral Benzodiazepine Receptor in Primate Brain
Zhang, M., Maeda, J., Ogawa, M., Noguchi, J., Ito, T., Yoshida, Y., Okauchi, T., Obayashi, S., Suhara, T., & Suzuki, K. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0304919 · Cited by 147 · see citing works
Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay
Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Voorde, A., Martin, J.-J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 145 · see citing works
Trajectories of brain loss in aging and the development of cognitive impairment
Carlson, N. E., Moore, M. M., Dame, A., Howieson, D., Silbert, L. C., Quinn, J. F., & Kaye, J. A. (2008) · Neurology · doi:10.1212/01.wnl.0000280577.43413.d9 · Cited by 144 · see citing works
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease
Kadir, A., Andreasen, N., Almkvist, O., Wall, A. E., Forsberg, A., Engler, H., Hagman, G., Lärksäter, M., Winblad, B. G., Zetterberg, H., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21345 · Cited by 133 · see citing works
Expression of monoamine oxidase B activity in astrocytes of senile plaques
Nakamura, S., Kawamata, T., Akiguchi, I., Kameyama, M., Nakamura, N., & Kimura, H. (1990) · Acta Neuropathologica · doi:10.1007/bf00307697 · Cited by 131 · see citing works
Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer’s disease
Abe, T., Tohgi, H., Isobe, C., Murata, T., & Sato, C. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10349 · Cited by 124 · see citing works
The Magnitude of Brain Lipid Peroxidation Correlates with the Extent of Degeneration but Not with Density of Neuritic Plaques or Neurofibrillary Tangles or with APOE Genotype in Alzheimer's Disease Patients
Montine, T. J., Markesbery, W. R., Zackert, W. E., Sanchez, S. C., Roberts, L. J., & Morrow, J. D. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65185-1 · Cited by 116 · see citing works
Complement activation in very early Alzheimer disease
Zanjani, H., Finch, C. E., Kemper, C., Atkinson, J., McKeel, D., Morris, J. C., & Price, J. L. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000165506.60370.94 · Cited by 115 · see citing works
Plasma and cerebrospinal fluid α1‐antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment
DeKosky, S. T., Ikonomović, M. D., Wang, X., Farlow, M. R., Wisniewski, S. R., López, O. L., Becker, J. T., Saxton, J. A., Klunk, W. E., Sweet, R. A., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10414 · Cited by 97 · see citing works
Longitudinal CSF isoprostane and MRI atrophy in the progression to AD
de Leon, M. J., Mosconi, L., Li, J., Santi, S. D., Yao, Y., Tsui, W.-H., Pirraglia, E., Rich, K. E., Javier, E., Bryś, M., et al. (2007) · Journal of Neurology · doi:10.1007/s00415-007-0610-z · Cited by 82 · see citing works
Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta
Kauwe, J. S. K., Wang, J., Mayo, K., Morris, J. C., Fagan, A. M., Holtzman, D. M., & Goate, A. M. (2009) · neurogenetics · doi:10.1007/s10048-008-0150-4 · Cited by 82 · see citing works
Self-citation
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease
Thambisetty, M., Hye, A., Foy, C., Daly, E., Glover, A., Cooper, A., Simmons, A., Murphy, D., & Lovestone, S. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0006-8 · Cited by 80 · see citing works
Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry
Portelius, E., Hansson, S., Tran, A. J., Zetterberg, H., Grognet, P., Vanmechelen, E., Höglund, K., Brinkmalm, G., Brinkmalm, A., Nordhoff, E., et al. (2008) · Journal of Proteome Research · doi:10.1021/pr7008669 · Cited by 79 · see citing works
Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease
Hu, Y., Hosseini, A., Kauwe, J. S. K., Gross, J., Cairns, N. J., Goate, A., Fagan, A. M., Townsend, R. R., & Holtzman, D. M. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200600999 · Cited by 75 · see citing works
Self-citation
Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: Preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients
Vas, Á., Shchukin, Y., Karrenbauer, V. D., Cselényi, Z., Kostulas, K., Hillert, J. A., Savić, I., Takano, A., Halldin, C., & Gulyás, B. Z. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.07.018 · Cited by 71 · see citing works
Assessment of MAO-B Occupancy in the Brain With PET and [11C]-L-Deprenyl-D2: A Dose-Finding Study With a Novel MAO-B Inhibitor, EVT 301
Hirvonen, J., Kailajärvi, M., Haltia, T., Koskimies, S., Någren, K., Virsu, P., Oikonen, V., Sipilä, H. T., Ruokoniemi, P. T., Virtanen, K. A., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.241 · Cited by 64 · see citing works
About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson)
Jarvik, L. F., & Alzheimer, A. (1987) · PubMed · Cited by 64 · see citing works
Targeted proteomics in Alzheimer’s disease: focus on amyloid-β
Portelius, E., Zetterberg, H., Gobom, J., Andréasson, U., & Blennow, K. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.225 · Cited by 51 · see citing works
Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state
Smyth, M. D., Cribbs, D. H., Tenner, A. J., Shankle, W. R., Dick, M. B., Kesslak, J. P., & Cotman, C. W. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)00055-7 · Cited by 49 · see citing works
The subunits of α2-macroglobulin receptor/low density lipoprotein receptor-related protein, native and transformed α2-macroglobulin and interleukin 6 in Alzheimer's disease
Thal, D. R., Schober, R., & Birkenmeier, G. (1997) · Brain Research · doi:10.1016/s0006-8993(97)01021-4 · Cited by 39 · see citing works
Cerebrospinal Fluid C3a Increases with Age, But Does Not Increase Further in Alzheimer’s Disease
Loeffler, D. A., Brickman, C. M., Juneau, P. L., Perry, M. F., Pomara, N., & LeWitt, P. A. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00110-3 · Cited by 31 · see citing works
Handbook of Dementing Illnesses
Kawas, C. H., & Corrada, M. (2006) · CRC Press eBooks · doi:10.3109/9780849354847
Untitled work
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Untitled work
(2000) · doi:10.1002/1531-8249(200011)48:5
Untitled work
(2000) · doi:10.1002/1531-8249(200012)48:6

Flagged first, then by citations

Research works printed but not linked: 6

[1]Alzheimer A (Translated by Jarvik, L.a.G., H.). ber eine eignartige Erkrankung der Hirnrinde. (About a peculiar disease of the cerebral cortex.) Alzheimer Dis. Assoc. Disorders 1987 1 7 8 3331112
[19]Mintun M [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease Neurology 2006 67 446 52 16894106
[20]Fagan A Inverse relation between in vivo amyloid imaging load and CSF Aβ42 in humans Ann Neurol 2006 59 512 519 16372280This study illustrates an inverse relationship between mean cortical retention of amyloid-imaging PET tracer compound PIB and CSF Aβ42 levels among both demented and non-demented subjects, suggesting that brain amyloid deposition results in low CSF Aβ42 and that amyloid imaging and CSF Aβ42 might serve as antecedent biomarkers of preclinical AD.
[46]Mayeux R Plasma amyloid beta-peptide 1-42 and incipient Alzheimer’s disease Ann Neurol 1999 46 412 6 10482274
[51]Pratico D V MYL Trojanowski JQ Rokach J Fitzgerald GA Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid peroxidation in vivo FASEB J 1998 12 1777 83 9837868
[54]Montine TJ No difference in plasma or urinary F2-isoprostanes among patients with Huntington’s disease or Alzheimer’s disease and controls Ann Neurol 2000 48 950 11117557

Sorted by citations

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396 · see citing works
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · see citing works
Self-citation
Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · see citing works
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · see citing works
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · see citing works
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · see citing works
Self-citation
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,227 · see citing works
“Because effective AD treatments will likely depend on intervening during the preclinical (presymptomatic) phase of AD (44, 45), understanding how environmental and genetic risk factors modulate pathological hallmarks of the disease will be critical.”
Self-citation
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002 · see citing works
Self-citation
Hierarchical Feature Representation and Multimodal Fusion with Deep Learning for AD/MCI Diagnosis
Suk, H.-I., Lee, S.-W., & Shen, D. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.06.077 · Cited by 968 · see citing works
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931 · see citing works
New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation
Zisapel, N. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14116 · Cited by 893 · see citing works
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857 · see citing works
Self-citation
Drivers of biodiagnostic development
Giljohann, D. A., & Mirkin, C. A. (2009) · Nature · doi:10.1038/nature08605 · Cited by 745 · see citing works
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738 · see citing works
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734 · see citing works
Self-citation
Multimodal deep learning models for early detection of Alzheimer’s disease stage
Venugopalan, J., Tong, L., Hassanzadeh, H. R., & Wang, M. D. (2021) · Scientific Reports · doi:10.1038/s41598-020-74399-w · Cited by 732 · see citing works
Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664 · see citing works
Trusted Multi-View Classification With Dynamic Evidential Fusion
Han, Z., Zhang, C., Fu, H., & Zhou, J. T. (2022) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2022.3171983 · Cited by 661 · see citing works
Regulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639 · see citing works
A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages
Rathore, S., Habes, M., Iftikhar, M. A., Shacklett, A., & Davatzikos, C. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.03.057 · Cited by 622 · see citing works
An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease
Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602 · see citing works
Loss of intranetwork and internetwork resting state functional connections with Alzheimer’s disease progression
Brier, M. R., Thomas, J. B., Snyder, A. Z., Benzinger, T. L., Zhang, D., Raichle, M. E., Holtzman, D. M., Morris, J. C., & Ances, B. M. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5698-11.2012 · Cited by 595 · see citing works
Self-citation
The Neuropsychological Profile of Alzheimer DiseasePreprint
Weıntraub, S., Wicklund, A. H., & Salmon, D. P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006171 · Cited by 569 · see citing works
Latent feature representation with stacked auto-encoder for AD/MCI diagnosis
Initiative, T. A. D. N., Suk, H., Lee, S., & Shen, D. G. (2013) · Brain Structure and Function · doi:10.1007/s00429-013-0687-3 · Cited by 523 · see citing works
Structural Studies of Amyloid Proteins at the Molecular Level
Eisenberg, D. S., & Sawaya, M. R. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045104 · Cited by 513 · see citing works
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504 · see citing works
Self-citation
Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease
Koronyo, Y., Biggs, D., Barrón, E., Boyer, D. S., Pearlman, J. A., Au, W. J., Kile, S. J., Blanco, A., Fuchs, D.-T. S., Ashfaq, A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93621 · Cited by 504 · see citing works
Brain MRI analysis for Alzheimer’s disease diagnosis using an ensemble system of deep convolutional neural networks
Islam, J., & Zhang, Y. (2018) · Brain Informatics · doi:10.1186/s40708-018-0080-3 · Cited by 491 · see citing works
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473 · see citing works
Circadian rest-activity pattern changes in aging and preclinical Alzheimer disease
Musiek, E. S., Bhimasani, M., Zangrilli, M. A., Morris, J. C., Holtzman, D. M., & Ju, Y.-E. S. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4719 · Cited by 465 · see citing works
Self-citation
Deep Learning-Based Feature Representation for AD/MCI Classification
Suk, H., & Shen, D. G. (2013) · Lecture notes in computer science · doi:10.1007/978-3-642-40763-5_72 · Cited by 463 · see citing works
ApoE4 Accelerates Early Seeding of Amyloid Pathology
Liu, C.-C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C.-W., & Bu, G. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.013 · Cited by 451 · see citing works
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
de la Monte, S. M. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 446 · see citing works
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434 · see citing works
Self-citation
Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes
Jun, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.201 · Cited by 422 · see citing works
Brain β-amyloid load approaches a plateau
Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406 · see citing works
The benefits and limitations of animal models for translational research in neurodegenerative diseases
Jucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401 · see citing works
Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382 · see citing works
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia
La Joie, R., Perrotin, A., Barré, L., Hommet, C., Mézenge, F., Ibazizene, M., Camus, V., Abbas, A., Landeau, B., Guilloteau, D., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2170-12.2012 · Cited by 374 · see citing works
In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice
Yamada, K., Cirrito, J. R., Stewart, F. R., Jiang, H., Finn, M. B., Holmes, B. B., Binder, L. I., Mandelkow, E.-M., Diamond, M. I., Lee, V. M.-Y., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2569-11.2011 · Cited by 351 · see citing works
Self-citation
Utility of Combinations of Biomarkers, Cognitive Markers, and Risk Factors to Predict Conversion From Mild Cognitive Impairment to Alzheimer Disease in Patients in the Alzheimer's Disease Neuroimaging Initiative
Gomar, J. J. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.96 · Cited by 340 · see citing works
Apolipoprotein E4 Causes Age- and Tau-Dependent Impairment of GABAergic Interneurons, Leading to Learning and Memory Deficits in Mice
Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S. Y., Zwilling, D., Yan, T. X., Chen, L., & Huang, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4040-10.2010 · Cited by 326 · see citing works
S-Glutathionylation: From Molecular Mechanisms to Health Outcomes
Xiong, Y., Uys, J. D., Tew, K. D., & Townsend, D. M. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3540 · Cited by 314 · see citing works
Persistent, Long-term Cerebral White Matter Changes after Sports-Related Repetitive Head Impacts
Bazarian, J. J., Zhu, T., Zhong, J., Janigro, D., Rozen, E., Roberts, A., Javien, H., Merchant‐Borna, K., Abar, B. W., & Blackman, E. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094734 · Cited by 300 · see citing works
Suspected non-Alzheimer disease pathophysiology — concept and controversy
Jack, C. R., Knopman, D. S., Chételat, G., Dickson, D. W., Fagan, A. M., Frisoni, G. B., Jagust, W. J., Mormino, E. C., Petersen, R. C., Sperling, R. A., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.251 · Cited by 299 · see citing works
Self-citation
The Pericyte: A Forgotten Cell Type with Important Implications for A lzheimer's Disease?
Winkler, E. A., Sagare, A. P., & Zloković, B. V. (2014) · Brain Pathology · doi:10.1111/bpa.12152 · Cited by 275 · see citing works
Effective feature learning and fusion of multimodality data using stage‐wise deep neural network for dementia diagnosis
Zhou, T., Thung, K., Zhu, X., & Shen, D. G. (2018) · Human Brain Mapping · doi:10.1002/hbm.24428 · Cited by 270 · see citing works
Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimerʼs Disease
de la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265 · see citing works
Modification of the Relationship of the Apolipoprotein E ε4 Allele to the Risk of Alzheimer Disease and Neurofibrillary Tangle Density by Sleep
Lim, A. S. P., Yu, L., Kowgier, M. E., Schneider, J. A., Buchman, A. S., & Bennett, D. A. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4215 · Cited by 260 · see citing works
Ocular indicators of Alzheimer’s: exploring disease in the retina
Hart, N. J., Koronyo, Y., Black, K. L., & Koronyo‐Hamaoui, M. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1613-6 · Cited by 260 · see citing works
Models of β-amyloid induced Tau-pathology: The long and “folded” road to understand the mechanism
Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-51 · Cited by 256 · see citing works
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB–PET longitudinal study
Villain, N., Chételat, G., Grassiot, B., Bourgeat, P., Jones, G., Ellis, K. A., Ames, D., Martins, R. N., Eustache, F., Salvado, O., et al. (2012) · Brain · doi:10.1093/brain/aws125 · Cited by 255 · see citing works
Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging
Choi, H., & Jin, K. H. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.02.017 · Cited by 255 · see citing works
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251 · see citing works
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Kester, M. I., Teunissen, C. E., Crimmins, D. L., Herries, E. M., Ladenson, J. H., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1867 · Cited by 246 · see citing works
Self-citation
Multi-modal deep learning model for auxiliary diagnosis of Alzheimer’s disease
Zhang, F., Li, Z., Zhang, B., Du, H., Wang, B., & Zhang, X. (2019) · Neurocomputing · doi:10.1016/j.neucom.2019.04.093 · Cited by 238 · see citing works
Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis
Craig‐Schapiro, R., Kühn, M., Xiong, C., Pickering, E. H., Liu, J., Misko, T. P., Perrin, R. J., Bales, K. R., Soares, H. D., Fagan, A. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018850 · Cited by 235 · see citing works
Self-citation
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
Hu, W. T., Holtzman, D. M., Fagan, A. M., Shaw, L. M. J., Perrin, R. J., Arnold, S. E., Grossman, M., Xiong, C., Craig‐Schapiro, R., Clark, C. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318266fa70 · Cited by 234 · see citing works
Self-citation
Multimodality Review of Amyloid-related Diseases of the Central Nervous System
Miller‐Thomas, M. M., Sipe, A. L., Benzinger, T. L. S., McConathy, J., Connolly, S., & Schwetye, K. E. (2016) · Radiographics · doi:10.1148/rg.2016150172 · Cited by 234 · see citing works
Influence of comorbidities in idiopathic normal pressure hydrocephalus — research and clinical care. A report of the ISHCSF task force on comorbidities in INPH
Malm, J., Graff‐Radford, N. R., Ishikawa, M., Kristensen, B. W., Leinonen, V., Mori, E., Owler, B., Tullberg, M., Williams, M. A., & Relkin, N. R. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-22 · Cited by 228 · see citing works
Developing Therapeutic Antibodies for Neurodegenerative Disease
Yu, Y. J., & Watts, R. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0187-4 · Cited by 227 · see citing works
Latent Representation Learning for Alzheimer’s Disease Diagnosis With Incomplete Multi-Modality Neuroimaging and Genetic Data
Zhou, T., Liu, M., Thung, K., & Shen, D. G. (2019) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2019.2913158 · Cited by 226 · see citing works
A novel relational regularization feature selection method for joint regression and classification in ad diagnosis
Zhu, X., Suk, H.-I., Wang, L., Lee, S.-W., & Shen, D. (2017) · Medical Image Analysis · doi:10.1016/j.media.2015.10.008 · Cited by 224 · see citing works
Evidence for Ordering of Alzheimer Disease Biomarkers
Jack, C. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.183 · Cited by 221 · see citing works
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease
Tarawneh, R. M., D’Angelo, G., Crimmins, D. L., Herries, E. M., Griest, T. A., Fagan, A. M., Zipfel, G. J., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0086 · Cited by 219 · see citing works
Self-citation
Vitamin B1 (thiamine) and dementia
Gibson, G. E., Hirsch, J. A., Fonzetti, P., Jordan, B. D., Cirio, R. T., & Elder, J. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13031 · Cited by 214 · see citing works
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211 · see citing works
Early Alzheimer's Disease
Mayeux, R. P. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0910236 · Cited by 208 · see citing works
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
Hansson, O., Hall, S., Öhrfelt, A., Zetterberg, H., Blennow, K., Minthon, L., Nägga, K., Londos, E., Varghese, S., Majbour, N. K., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt255 · Cited by 208 · see citing works
The Choroid Plexus and Cerebrospinal Fluid: Emerging Roles in Development, Disease, and Therapy
Lehtinen, M. K., Bjornsson, C. S., Dymecki, S. M., Gilbertson, R. J., Holtzman, D. M., & Monuki, E. S. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3258-13.2013 · Cited by 204 · see citing works
Self-citation
Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide
Sharma, A. K., Pavlova, S. T., Kim, J., Finkelstein, D., Hawco, N. J., Rath, N. P., Kim, J., & Mirica, L. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210588m · Cited by 202 · see citing works
Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease
Gallardo, G., & Holtzman, D. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_16 · Cited by 201 · see citing works
Self-citation
Midlife sleep characteristics associated with late life cognitive function
Virta, J. J., Heikkilä, K., Perola, M., Koskenvuo, M., Räihä, I., Rinne, J. O., & Kaprio, J. (2013) · Sleep · doi:10.5665/sleep.3052 · Cited by 200 · see citing works
CSF Biomarkers for Alzheimer's Disease Diagnosis
Arunagiri, A., Singh, P. K., Jacob, R. S., & Maji, S. K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/606802 · Cited by 197 · see citing works
Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community
Petersen, R. C., Wiste, H. J., Weigand, S. D., Rocca, W. A., Roberts, R. O., Mielke, M. M., Lowe, V. J., Knopman, D. S., Pankratz, V. S., Machulda, M. M., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3098 · Cited by 196 · see citing works
Immunotherapy for Alzheimer’s disease: hoops and hurdles
Lemere, C. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-36 · Cited by 196 · see citing works
Predicting Progression from Mild Cognitive Impairment to Alzheimer's Dementia Using Clinical, MRI, and Plasma Biomarkers via Probabilistic Pattern Classification
Korolev, I. O., Symonds, L. L., Bozoki, A., & Initiative, A. D. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0138866 · Cited by 192 · see citing works
Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology
Fagan, A. M., Shaw, L. M. J., Xiong, C., Vanderstichele, H., Mintun, M. A., Trojanowski, J. Q., Coart, E., Morris, J. C., & Holtzman, D. M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.105 · Cited by 190 · see citing works
Self-citation
The development and validation of tau PET tracers: current status and future directions
Okamura, N., Harada, R., Ishiki, A., Kikuchi, A., Nakamura, T., & Kudo, Y. (2018) · Clinical and Translational Imaging · doi:10.1007/s40336-018-0290-y · Cited by 183 · see citing works
Neuroinflammation in Alzheimer’s disease; A source of heterogeneity and target for personalized therapy
Latta, C. H., Brothers, H. M., & Wilcock, D. M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.061 · Cited by 176 · see citing works
Optical Coherence Tomography in Alzheimer’s Disease and Other Neurodegenerative Diseases
Doustar, J., Torbati, T., Black, K. L., Koronyo, Y., & Koronyo‐Hamaoui, M. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00701 · Cited by 176 · see citing works
Sphingolipids: Critical players in Alzheimer’s disease
van Echten‐Deckert, G., & Walter, J. (2012) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.07.001 · Cited by 172 · see citing works
A leptin derived 30-amino-acid peptide modified pegylated poly-l-lysine dendrigraft for brain targeted gene delivery
Liu, Y., Li, J., Shao, K., Huang, R., Ye, L., Lou, J., & Jiang, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.03.011 · Cited by 172 · see citing works
Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People
Wirth, M., Villeneuve, S., Haase, C. M., Madison, C. M., Oh, H., Landau, S. M., Rabinovici, G. D., & Jagust, W. J. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4013 · Cited by 171 · see citing works
Tau PET Imaging in Alzheimer’s Disease
Okamura, N., Harada, R., Furumoto, S., Arai, H., Yanai, K., & Kudo, Y. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0500-6 · Cited by 169 · see citing works
Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity
Du, W., Guo, J., Gao, M., Hu, S., Dong, X., Han, Y., Liu, F., Jiang, S., & Sun, Y. P. (2015) · Scientific Reports · doi:10.1038/srep07992 · Cited by 169 · see citing works
Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease
Tarawneh, R. M., D’Angelo, G., Macy, E., Xiong, C., Carter, D. R., Cairns, N. J., Fagan, A. M., Head, D. M., Mintun, M. A., Ladenson, J. H., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22448 · Cited by 167 · see citing works
Self-citation
Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system
Dá Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., & Marques, F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.014 · Cited by 166 · see citing works
Deep sparse multi-task learning for feature selection in Alzheimer’s disease diagnosis
Initiative, T. A. D. N., Suk, H., Lee, S., & Shen, D. G. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1059-y · Cited by 164 · see citing works
Indicators of amyloid burden in a population-based study of cognitively normal elderly
Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., Geda, Y. E., Swenson-Dravis, D. M., Boeve, B. F., Senjem, M. L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e2696 · Cited by 163 · see citing works
Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease
Sutphen, C. L., McCue, L., Herries, E. M., Xiong, C., Ladenson, J. H., Holtzman, D. M., Fagan, A. M., & On behalf of, A. D. N. I. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.012 · Cited by 162 · see citing works
Self-citation
Comparative profiling of cortical gene expression in Alzheimer’s disease patients and mouse models demonstrates a link between amyloidosis and neuroinflammation
Castillo, E., Leon, J., Mazzei, G., Abolhassani, N., Haruyama, N., Saito, T., Saido, T., Hokama, M., Iwaki, T., Ohara, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17999-3 · Cited by 158 · see citing works
More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration
Lane-Donovan, C., Philips, G. T., & Herz, J. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.005 · Cited by 158 · see citing works
Episodic memory on the path to Alzheimer's disease
Gallagher, M., & Koh, M. T. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.10.021 · Cited by 156 · see citing works
Dementia of the eye: the role of amyloid beta in retinal degeneration
Ratnayaka, J. A., Serpell, L. C., & Lotery, A. J. (2015) · Eye · doi:10.1038/eye.2015.100 · Cited by 153 · see citing works
Maintenance of Amyloid β Peptide Homeostasis by Artificial Chaperones Based on Mixed‐Shell Polymeric Micelles
Huang, F., Wang, J., Qu, A., Shen, L., Liu, J., Liu, J., Zhang, Z., An, Y., & Shi, L. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201400735 · Cited by 152 · see citing works
Alzheimer's Disease Neurodegenerative Biomarkers Are Associated with Decreased Cognitive Function but Not β-Amyloid in Cognitively Normal Older Individuals
Wirth, M., Madison, C. M., Rabinovici, G. D., Oh, H., Landau, S. M., & Jagust, W. J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4409-12.2013 · Cited by 151 · see citing works
Multimodal neuroimaging computing: a review of the applications in neuropsychiatric disorders
Liu, S., Cai, W., Liu, S., Zhang, F., FULHAM, M., Feng, D., Pujol, S., & Kikinis, R. (2015) · Brain Informatics · doi:10.1007/s40708-015-0019-x · Cited by 150 · see citing works
Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease
Leinonen, V., Koivisto, A. M., Savolainen, S., Rummukainen, J. K., Tamminen, J. N., Tillgren, T., Vainikka, S., Pyykkö, O. T., Mölsä, J. A. A., zu Fraunberg, M. V. U., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22100 · Cited by 149 · see citing works
Alzheimer's Disease: A Clinical and Basic Science Review
Korolev, I. O. (2014) · Cited by 146 · see citing works

Neuroimaging Advances in Preclinical Alzheimers disease
Sheng, C., Huang, Y. M., Li, H., Sun, Y., Chen, Q., Ma, C., Liu, F., & Han, Y. (2018) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000508
Advanced Techniques for the Early Detection of Alzheimer’s Disease Using Neuroimaging and Machine Learning
Shah, V. R., Satapathy, S. K., Mohapatra, R. K., Brahma, B., & Bhoi, A. K. (2025) · Studies in computational intelligence · doi:10.1007/978-3-031-99946-8_6 · Cited by 1 · see citing works
Biomarker Research of Preclinical Alzheimer’s Disease and MCI Based on Neuroimage Techniques
Wu, X., Guo, X., Lai, Y., Chen, K., & Li, Y. (2014) · Neuroscience and Biomedical Engineering · doi:10.2174/2213385202666140207002924
Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection
Teipel, S. J., Drzezga, A. E., Grothe, M. J., Barthel, H., Chételat, G., Schuff, N. W., Skudlarski, P., Cavedo, E., Frisoni, G. B., Hoffmann, W. U., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00093-9 · Cited by 263 · see citing works
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia
Ewers, M., Sperling, R. A., Klunk, W. E., Weiner, M. W., & Hampel, H. J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.05.005 · Cited by 345 · see citing works

Authors: Perrin, R. J., Fagan, A. M., & Holtzman, D. M.
Affiliations: Washington University in St. Louis (US)
ORCID: Perrin, Richard J.
Fagan, Anne M.
Holtzman, David M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2009-10
Volume: 461
Issue: 7266
Pages: 916-922
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature08538
PMC: PMC2810658
OpenAlex: W2085558649
Cited by: 702
References: 83
Citations by year: 2026: 20 · 2025: 29 · 2024: 30 · 2023: 28 · 2022: 43 · 2021: 56 · 2020: 38 · 2019: 38 · 2018: 36 · 2017: 48 · 2016: 33 · 2015: 49 · 2014: 53 · 2013: 58 · 2012: 60
FWCI: 5.97
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: National Institutes of Health (5t32ns007205-32)
National Institute on Aging (P50AG005681, P01 AG0 3991, P01AG003991, P50AG00568125, P01AG026276)
National Institute of Neurological Disorders and Stroke (T32-NS007205)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords: Alzheimer's disease, multimodal diagnosis, prognosis, neuroimaging, fluid biomarkers, preclinical detection, protein misfolding, neurodegeneration, dementia, clinical trials
MeSH terms: Alzheimer Disease, Humans, Inflammation, Prognosis, Amyloid beta-Peptides, tau Proteins, Oxidative Stress, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks